Results 81 to 90 of about 529,650 (310)

Impact of copper and iron binding properties on the anticancer activity of 8-hydroxyquinoline derived Mannich bases. [PDF]

, 2018
The anticancer activity of 8-hydroxyquinolines relies on complex formation with redox active copper and iron ions. Here we employ UV-visible spectrophotometry and EPR spectroscopy to compare proton dissociation and complex formation processes of the ...
Enyedy, Éva A., Fülöp, Ferenc, Gál, G. Tamás, May, Nóra V., Pape, Veronika F.S., Szakács, Gergely, Szatmári, István, Szeri, Flóra   +7 more
core   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis [PDF]

, 2012
Recent data from the AZURE, ABCSG-12, and ZO-FAST clinical trials have challenged our understanding of the potential anticancer activity of zoledronic acid (ZOL). Although the results of these studies may appear to be conflicting on the surface, a deeper
Arrington, Avcu, Baum, Bilezikjian, Binkley, Bismar, Black, Bourdeau, Brown, Bundred, Burger, Burger, Centrella, Chapman, Cheleuitte, Chiu, Clowes, Coleman, Coscia, Coxon, Croucher, de Boer, Del Mastro, Dixon, Duivenvoorden, Edlund, Edlund, Esparza-Lopez, Folkerd, Gasser, Gasser, Geisler, Giraudo, Gnant, Gnant, Gnant, Gnant, Gordon, Guo, Hackshaw, Hamilton, Hampl, Hershman, Hershman, Hines, Hiraga, Hofbauer, Hornby, Ibrahim, Jimenez-Gordo, Juarez, Kaplan, Kaplan, Kardassis, Khosla, Kirkbride, Labrinidis, Le Goff, Lee, Lewis, Lindberg, Little, Little, Meads, Melani, Monkkonen, Muller, Nicks, Ogata, Ottewell, Ottewell, Ottewell, Pataki, Perrien, Perrien, Peyruchaud, Pfeilschifter, Podworny, Rachner, Rannevik, Roelofs, Rogers, Rosen, Rosen, Saika, Sasser, Sasser, Shiozawa, Shipman, Sims, Sirola, Skerjanec, Sowers, Studebaker, Sun, Tang, Thompson, Thurlimann, Uncu, van de Velde, Weiss, Wels, Welt, Wiater, Winter   +104 more
core   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Anticancer and apoptosis-inducing effects of Moringa concanensis using hepG2 cell lines

Bangladesh Journal of Pharmacology, 2014
The objective of the present investigation is focused on the anticancer activity of the ethanolic crude extract of Moringa concanensis leaf and bark against HepG2 cell line.
V. Balamurugan, Veluchamy Balakrishnan, J. Philip Robinson, M. Ramakrishnan   +3 more
doaj   +2 more sources

Synthesis and biological profile of substituted benzimidazoles

Chemistry Central Journal, 2018
Background A series of benzimidazole derivatives was developed and its chemical scaffolds were authenticated by NMR, IR, elemental analyses and physicochemical properties.
Neelam Vashist, Surinder Singh Sambi, Balasubramanian Narasimhan, Sanjiv Kumar, Siong Meng Lim, Syed Adnan Ali Shah, Kalavathy Ramasamy, Vasudevan Mani   +7 more
doaj   +1 more source

Anticancer activity of Nigerian medicinal plants: a review

Future Journal of Pharmaceutical Sciences, 2021
Background Cancer is currently the leading cause of death globally and the number of deaths from cancer is on the rise daily. Medicinal plants have been in continuous use over the years for the management of cancer, particularly, in most developing ...
Franklyn O. Ohiagu, Paul C. Chikezie, Chinwendu M. Chikezie, Christian E. Enyoh   +3 more
doaj   +1 more source

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. [PDF]

, 2018
The goal of anticancer therapy is to selectively eradicate all malignant cells. Unfortunately for the majority of patients with metastatic disease, this goal is consistently thwarted by the nearly inevitable development of therapeutic resistance; the ...
Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Oronsky, Arnold, Oronsky, Bryan, Reid, Tony R   +5 more
core   +2 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source